MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation

Investigative Radiology

Volumn 34, Issue 6, 1999, Pages 427-434

  Tynninen, Olli ^c   Aronen, Hannu J ^c   Ruhala, Marko ^c   Paetau, Anders ^c   Von Boguslawski, Kristina ^c   Salonen, Oili ^c   Jääskeläinen, Juha ^a   Paavonen, Timo ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NONE

Author keywords

Cell proliferation; Glioma; Immunohistochemistry; MR imaging; Neovascularization

Indexed keywords

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CONTRAST ENHANCEMENT; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0032916008     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199906000-00007     Document Type: Article

References (43)

1. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-761.
2. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
3. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
4. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-146.
5. Schiffer D, Chio A, Giordana MT, Leone M, Soffietti R. Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer 1988;61:1386-1393.
6. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77: 362-372.
7. Carr DH, Brown J, Bydder GM, Weinmann HJ, Speck U, Thomas DJ, Young IR. Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours. Lancet 1984;1:484-486.
8. Felix R, Schörner W, Laniado M, et al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985;156:681-688.
9. Schwaighofer BW, Klein MV, Wesbey G, Hesselink JR. Clinical experience with routine Gd-DTPA administration for MR imaging of the brain. J Comput Assist Tomogr 1990;14:11-17.
10. Graif M, Bydder GM, Steiner RE, Niendorf P, Thomas DG, Young IR. Contrast-enhanced MR imaging of malignant brain tumors. AJNR 1985;6:855-862.
11. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463-469.
12. Sage MR. Blood-brain barrier: Phenomenon of increasing importance to the imaging clinician. AJR 1982;138:887-898.
13. Atlas SW. Magnetic resonance imaging of the brain and spine. New York: Raven, 1991;223-326.
14. Asari S, Makabe T, Katayama S, Itoh T, Tsuchida S, Ohmoto T. Assessment of the pathological grade of astrocytic gliomas using an MRI score. Neuroradiology 1994;36:308-310.
15. Dean BL, Drayer BP, Bird CR, et al. Gliomas: Classification with MR imaging. Radiology 1990;174:411-415.
16. Brant-Zawadzki M, Berry I, Osaki L, Brasch R, Murovic J, Norman D. Gd-DTPA in clinical MR of the brain: I. Intraaxial lesions. AJR 1986;147:1223-1230.
17. Brant-Zawadzki M. Pitfalls of contrast-enhanced imaging in the nervous system. Magn Reson Med 1991;22:243-248.
18. Lee BC, Kneeland JB, Cahill PT, Deck MD. MR recognition of supratentorial tumors. AJNR 1985;6:871-878.
19. Barker FG 2nd, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936-941.
20. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: Histopathological evaluation of a series. Surg Neurol 1998;49:436-440.
21. Passe TJ, Bluemke DA, Siegelman SS. Tumor angiogenesis: Tutorial on implications for imaging. Radiology 1997;203:593-600.
22. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
23. Aronen HJ, Glass J, Pardo FS, et al. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. Acta Radiol 1995;36: 520-528.
24. Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR 1996;17:831-840.
25. Rosen BR, Aronen HJ. MRI perfusion studies of the brain. In: Thrall JH, ed. Current practice of radiology. St. Louis: Mosby-Year Book, Inc., 1993;512-519.
26. Brasch RC, Daldrup H, Shames D, Wendland M, Okuhata Y, Rosenau W. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. Acad Radiol 1998;5(suppl 1):S2-S5.
27. Frouge C, Guinebretiere JM, Contesso G, Di Paola R, Blery M. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol 1994;29:1043-1049.
28. Hawighorst H, Knapstein PG, Weikel W, et al. Angiogenesis of uterine cervical carcinoma: Characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997;57:4777-4786.
29. Nägele T, Petersen D, Klose U, et al. Dynamic contrast enhancement of intracranial tumors with snapshot-FLASH MR imaging. AJNR 1993;14:89-98.
30. Fujimaki T, Matsutani M, Nakamura O, et al. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults. Cancer 1991;67:1629-1634.
31. Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson CB. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer 1993;53: 550-555.
32. Danova M, Riccardi A, Mazzini G, et al. Ploidy and proliferative activity of human brain tumors. A flow cytofluorometric study. Oncology 1987;44:102-107.
33. Hoyt JW, Gown AM, Kim DK, Berger MS. Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin-fixed, deparaffinized tissues. J Neurooncol 1995;24:163-169.
34. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study. Acta Neuropathol 1991;81:675-679.
35. Parkins CS, Darling JL, Gill SS, Revesz T, Thomas DG. Cell proliferation in serial biopsies through human malignant brain tumours: Measurement using Ki-67 antibody labelling. BrJ Neurosurg 1991; 5:289-298.
36. Zuber P, Hamou MF, de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988;22:364-368.
37. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 1989;115:179-188.
38. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system, ed. 2. Berlin: Springer-Verlag, 1993.
39. Kleihues P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer, 1997;16-24.
40. Aronen HJ, Cohen MS, Belliveau JW, Fordham JA, Rosen BR. Ultrafast imaging of brain tumors. Top Magn Reson Imaging 1993; 5:14-24.
41. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997;56:798-805.
42. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-618.
43. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485-491.